Xenotransplantation literature update, November/December 2019.
Animals
Animals, Genetically Modified
Clustered Regularly Interspaced Short Palindromic Repeats
Complement System Proteins
/ metabolism
Humans
Immune Tolerance
Mesenchymal Stem Cells
/ physiology
Organ Transplantation
Primates
Swine
Tissue Engineering
/ methods
Transplantation, Heterologous
/ methods
CRISPR
Mesenchymal stem cells
complement regulation
zoonosis
Journal
Xenotransplantation
ISSN: 1399-3089
Titre abrégé: Xenotransplantation
Pays: Denmark
ID NLM: 9438793
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
28
12
2019
accepted:
14
01
2020
pubmed:
28
1
2020
medline:
21
5
2021
entrez:
28
1
2020
Statut:
ppublish
Résumé
The ever-increasing disparity between the lack of organ donors and patients on the transplant waiting list is increasing worldwide. For the past several decades xenotransplantation has led the way to correct this deficit and remains clearly the only feasible option to provide a means to meet the demand for patients in need of an organ transplant. Xenotransplantation's ability to provide a specifically designed unlimited supply of organs, suited to treat the various needs for transplant organs and cells, has recently been championed by successful pre-clinical trials that have run long-term in non-human primate studies. In this review we show how these improvements have come about due to long-term dedicated research and recent advances in biomedical engineering technology, such as genome editing tools including zinc finger nucleases, TALEN, and CRISPER/Cas9 which have paved the way for significant breakthroughs in improving xenograft outcomes through genetic modifications to the donor source pig. Other novel approaches include the development of decellularized porcine tissue, such as corneas which can now be transplanted into patients with the minimal need for immunosuppression or other side effects. Further genetic variants of the porcine genome are also now being optimized to abrogate rejection. The emergence of new modalities such as; mesenchymal stem cells, donor thymic vascularization, in vivo bioreactors, chemokine and cytokine therapies have come to show improvements in xenograft outcomes. Furthermore, new studies confirm the safety status of using porcine xenografts, verifying that with current technologies and approaches, the issue of PERV transmission is a moot point. These breakthroughs and technological advancements push the reality of xenotransplantation one step closer to the clinic.
Substances chimiques
Complement System Proteins
9007-36-7
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12582Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Ekser B, Cooper DKC, Tector AJ. The need for xenotransplantation as a source of organs and cells for clinical transplantation. Int J Surg. 2015;23(Pt B):199-204.
Cooper DK, Ayares D. The immense potential of xenotransplantation in surgery. Int J Surg. 2011;9(2):122-129.
Diamond LE, Quinn CM, Martin MJ, Lawson J, Platt JL, Logan JS. A human CD46 transgenic pig model system for the study of discordant xenotransplantation. Transplantation. 2001;71(1):132-142.
Lai L, Kolber-Simonds D, Park KW, et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science. 2002;295(5557):1089-1092.
Menoret S, Plat M, Blancho G, et al. Characterization of human CD55 and CD59 transgenic pigs and kidney xenotransplantation in the pig-to-baboon combination. Transplantation. 2004;77(9):1468-1471.
Mohiuddin MM. Clinical xenotransplantation of organs: why aren't we there yet? PLoS Med. 2007;4(3):e75.
Amano S, Shimomura N, Kaji Y, Ishii K, Yamagami S, Araie M. Antigenicity of porcine cornea as xenograft. Curr Eye Res. 2003;26(6):313-318.
De Stefano VS, Dupps WJ Jr. Biomechanical diagnostics of the cornea. Int Ophthalmol Clin. 2017;57(3):75-86.
Lee HI, Kim MK, Oh JY, et al. Gal alpha(1-3)Gal expression of the cornea in vitro, in vivo and in xenotransplantation. Xenotransplantation. 2007;14(6):612-618.
Feinberg AW. Engineered tissue grafts: opportunities and challenges in regenerative medicine. Wiley Interdiscip Rev Syst Biol Med. 2012;4(2):207-220.
Choi HJ, Lee JJ, Kim MK, et al. Cross-reactivity between decellularized porcine corneal lamellae for corneal xenobridging and subsequent corneal allotransplants. Xenotransplantation. 2014;21(2):115-123.
Zhang MC, Liu X, Jin Y, Jiang DL, Wei XS, Xie HT. Lamellar keratoplasty treatment of fungal corneal ulcers with acellular porcine corneal stroma. Am J Transplant. 2015;15(4):1068-1075.
Isidan A, Liu S, Li P, et al. Decellularization methods for developing porcine corneal xenografts and future perspectives. Xenotransplantation. 2019:26;e12564.
Shi W, Zhou Q, Gao H, et al. Protectively decellularized porcine cornea versus human donor cornea for lamellar transplantation. Adv Func Mater. 2019;29(37):1902491.
Gain P, Jullienne R, He Z, et al. Global Survey of Corneal Transplantation and Eye Banking. JAMA Ophthalmol. 2016;134(2):167-173.
Ekser B, Li P, Cooper DKC. Xenotransplantation: past, present, and future. Curr Opin Organ Transplant. 2017;22(6):513-521.
Hawthorne WJ, Lew AM, Thomas HE. Genetic strategies to bring islet xenotransplantation to the clinic. Curr Opin Organ Transplant. 2016;21(5):476-483.
Sake HJ, Frenzel A, Lucas-Hahn A, et al. Possible detrimental effects of beta-2-microglobulin knockout in pigs. Xenotransplantation. 2019;26:e12525.
Xie CW, Qu ZP, Hara H, et al. Downregulation of Gabarapl1 significantly attenuates antibody binding to porcine aortic endothelial cells. Xenotransplantation. 2019;26:e12537.
Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12(12):1063-1073.
Hoffmann U, Banas B, Kruger B, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human renal allograft rejection- a prospective study. Transpl Int. 2006;19(3):203-212.
Rangel EB, Moura LA, Franco M, Pacheco-Silva A. Expression of cyclooxygenases during renal allograft rejection. Transplant Proc. 2004;36(4):838-839.
Rangel EB, Moura LA, Franco MF, Pacheco-Silva A. Up-regulation of cyclooxygenase-2 during acute human renal allograft rejection. Clin Transplant. 2005;19(4):543-550.
Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271(52):33157-33160.
Chen P, Zhao Y, Gao H, et al. Selective inhibition of cyclooxygenase-2 protects porcine aortic endothelial cells from human antibody-mediated complement-dependent cytotoxicity. Xenotransplantation. 2019;26:e12536.
Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4-15.
Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol. 2004;68(2):341-350.
Cooper DKC, Ekser B, Tector AJ. Immunobiological barriers to xenotransplantation. Int J Surg. 2015;23(Pt B):211-216.
Oberholzer J, Yu D, Triponez F, et al. Decomplementation with cobra venom factor prolongs survival of xenografted islets in a rat to mouse model. Immunology. 1999;97(1):173-180.
Hawthorne WJ, Salvaris EJ, Phillips P, et al. Control of IBMIR in neonatal porcine islet xenotransplantation in baboons. Am J Transplant. 2014;14(6):1300-1309.
Meyer S, Leusen JH, Boross P. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs. 2014;6(5):1133-1144.
Samy KP, Gao Q, Davis RP, et al. The role of human CD46 in early xenoislet engraftment in a dual transplant model. Xenotransplantation. 2019;26:e12540.
Stevens MM, Marini RP, Schaefer D, Aronson J, Langer R, Shastri VP. In vivo engineering of organs: the bone bioreactor. Proc Natl Acad Sci U S A. 2005;102(32):11450-11455.
Masano Y, Yagi S, Miyachi Y, et al. Auxiliary xenotransplantation as an in vivo bioreactor-Development of a transplantable liver graft from a tiny partial liver. Xenotransplantation. 2019;26:e12545.
Yue Y, Kan Y, Weihong XU, et al. Extensive mammalian Germline genome engineering. BioRxiv. doi: https://doi.org/10.1101/2019.12.17.876862.
Bartsch O, Schneider E, Damatova N, et al. Fulminant hepatic failure requiring liver transplantation in 22q13.3 deletion syndrome. Am J Med Genet A. 2010;152A(8):2099-2102.
Arzouni AA, Vargas-Seymour A, Nardi N, J.F. King A, Jones PM. Using mesenchymal stromal cells in islet transplantation. Stem Cells Transl Med. 2018;7(8):559-563.
Kuo TK, Hung SP, Chuang CH, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008;134(7):2111-2121.
Lin NC, Wu HH, Ho JH, Liu CS, Lee OK. Mesenchymal stem cells prolong survival and prevent lethal complications in a porcine model of fulminant liver failure. Xenotransplantation. 2019;26:e12542.
Bottino R, Knoll MF, Knoll CA, Bertera S, Trucco MM. The Future of Islet Transplantation Is Now. Front Med (Lausanne). 2018;5:202.
Shin JS, Kim JM, Kim JS, et al. Long-term control of diabetes in immunosuppressed nonhuman primates (NHP) by the transplantation of adult porcine islets. Am J Transplant. 2015;15(11):2837-2850.
Kalscheuer H, Onoe T, Dahmani A, et al. Xenograft tolerance and immune function of human T cells developing in pig thymus xenografts. J Immunol. 2014;192(7):3442-3450.
Nikolic B, Gardner JP, Scadden DT, Arn JS, Sachs DH, Sykes M. Normal development in porcine thymus grafts and specific tolerance of human T cells to porcine donor MHC. J Immunol. 1999;162(6):3402-3407.
Zhao Y, Swenson K, Sergio JJ, Arn JS, Sachs DH, Sykes M. Skin graft tolerance across a discordant xenogeneic barrier. Nat Med. 1996;2(11):1211-1216.
Lee LA, Gritsch HA, Sergio JJ, et al. Specific tolerance across a discordant xenogeneic transplantation barrier. Proc Natl Acad Sci U S A. 1994;91(23):10864-10867.
Rivard CJ, Tanabe T, Lanaspa MA, et al. Upregulation of CD80 on glomerular podocytes plays an important role in development of proteinuria following pig-to-baboon xeno-renal transplantation - an experimental study. Transpl Int. 2018;31(10):1164-1177.
Sekijima M, Sahara H, Shimizu A, et al. Preparation of hybrid porcine thymus containing non-human primate thymic epithelial cells in miniature swine. Xenotransplantation. 2019;26:e12543.
Mok D, Black M, Gupta N, Arefanian H, Tredget E, Rayat GR. Early immune mechanisms of neonatal porcine islet xenograft rejection. Xenotransplantation. 2019;26(6):e12546.
Solomon MF, Kuziel WA, Mann DA, Simeonovic CJ. The role of chemokines and their receptors in the rejection of pig islet tissue xenografts. Xenotransplantation. 2003;10(2):164-177.
Wolf E, Kemter E, Klymiuk N, Reichart B. Genetically modified pigs as donors of cells, tissues, and organs for xenotransplantation. Animal Frontiers. 2019;9(3):13-20.
Lopata K, Wojdas E, Nowak R, Lopata P, Mazurek U. Porcine endogenous retrovirus (PERV) - molecular structure and replication strategy in the context of retroviral infection risk of human cells. Front Microbiol. 2018;9:730.
Denner J, Bigley TM, Phan TL, Zimmermann C, Zhou X, Kaufer BB. Comparative analysis of roseoloviruses in humans, pigs, mice, and other species. Viruses. 2019;11(12):1108.
Mueller NJ, Livingston C, Knosalla C, et al. Activation of porcine cytomegalovirus, but not porcine lymphotropic herpesvirus, in pig-to-baboon xenotransplantation. J Infect Dis. 2004;189(9):1628-1633.
Taylor RE, Gregg CJ, Padler-Karavani V, et al. Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid. J Exp Med. 2010;207(8):1637-1646.
Salama A, Evanno G, Harb J, Soulillou JP. Potential deleterious role of anti-Neu5Gc antibodies in xenotransplantation. Xenotransplantation. 2015;22(2):85-94.